Matches in Wikidata for { <http://www.wikidata.org/entity/Q92710039> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q92710039 description "artículu científicu espublizáu n'avientu de 2019" @default.
- Q92710039 description "scientific article published on 28 December 2019" @default.
- Q92710039 description "wetenschappelijk artikel" @default.
- Q92710039 description "наукова стаття, опублікована 28 грудня 2019" @default.
- Q92710039 description "գիտական հոդված հրատարակված 2019 թվականի դեկտեմբերի 28-ին" @default.
- Q92710039 name "Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study" @default.
- Q92710039 name "Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study" @default.
- Q92710039 type Item @default.
- Q92710039 label "Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study" @default.
- Q92710039 label "Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study" @default.
- Q92710039 prefLabel "Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study" @default.
- Q92710039 prefLabel "Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study" @default.
- Q92710039 P1433 Q92710039-816D7DA7-EB5D-449A-8C77-192164E273E2 @default.
- Q92710039 P1476 Q92710039-FDB24DA0-98FC-42D9-B6AA-8BCA9220B0BA @default.
- Q92710039 P2093 Q92710039-195CEF11-B2F7-4234-A761-7A9370462EE8 @default.
- Q92710039 P2093 Q92710039-34DAFF4B-F5F1-4398-8773-1B12D69BD36D @default.
- Q92710039 P2093 Q92710039-371A8637-CDE6-43EE-8986-B9EF54BB099B @default.
- Q92710039 P2093 Q92710039-37399C09-E59F-46F6-949C-701D6C46EEA0 @default.
- Q92710039 P2093 Q92710039-6C560ABE-B65A-464B-9FF5-CEF91BB1F9E2 @default.
- Q92710039 P2093 Q92710039-82A17F06-55B9-4303-B3B9-A022F602F5BA @default.
- Q92710039 P2093 Q92710039-C6418707-565C-4F09-B378-54638206F5B7 @default.
- Q92710039 P2093 Q92710039-F48A7896-0718-42D6-A793-3DA62AC1A7C3 @default.
- Q92710039 P304 Q92710039-B5C57E60-84B8-4766-BF1D-C30261748A4D @default.
- Q92710039 P31 Q92710039-01EB951B-C82A-46DD-B02E-089E62F862EE @default.
- Q92710039 P356 Q92710039-84F2FCFE-F18C-4C6B-9D2C-07AE5186C1DD @default.
- Q92710039 P433 Q92710039-A1EB1AFE-ACA8-4BAF-8B0F-253FC3004D00 @default.
- Q92710039 P478 Q92710039-03DB7622-DE65-4A1B-BAE9-9143DCD2D1A2 @default.
- Q92710039 P50 Q92710039-39CF30EA-BFC0-4E8F-AB6B-AFE4D0AC6C67 @default.
- Q92710039 P50 Q92710039-F409AAC7-ABFA-4EF1-9B89-E1FF2F257EF2 @default.
- Q92710039 P577 Q92710039-9E990C99-1830-46ED-9B83-569963F7924D @default.
- Q92710039 P698 Q92710039-2341D9B1-8643-485A-B884-CF549B45882A @default.
- Q92710039 P921 Q92710039-2FE6DDFC-7F39-413E-9E59-9744BB47E907 @default.
- Q92710039 P921 Q92710039-34B63319-4FAD-4882-A73C-F26A03722FCD @default.
- Q92710039 P921 Q92710039-AE6AB8B4-225F-4DBD-B232-B77C28E7C54A @default.
- Q92710039 P356 J.CLLC.2019.12.006 @default.
- Q92710039 P698 31948903 @default.
- Q92710039 P1433 Q332299 @default.
- Q92710039 P1476 "Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study" @default.
- Q92710039 P2093 "Gabriel Mak" @default.
- Q92710039 P2093 "Gyeong-Won Lee" @default.
- Q92710039 P2093 "Haiyi Jiang" @default.
- Q92710039 P2093 "Isamu Okamoto" @default.
- Q92710039 P2093 "Norah Shire" @default.
- Q92710039 P2093 "Seiji Niho" @default.
- Q92710039 P2093 "Wenliang Yao" @default.
- Q92710039 P2093 "Yuanbin Chen" @default.
- Q92710039 P304 "e84-e88" @default.
- Q92710039 P31 Q13442814 @default.
- Q92710039 P356 "10.1016/J.CLLC.2019.12.006" @default.
- Q92710039 P433 "2" @default.
- Q92710039 P478 "21" @default.
- Q92710039 P50 Q37830477 @default.
- Q92710039 P50 Q63775110 @default.
- Q92710039 P577 "2019-12-28T00:00:00Z" @default.
- Q92710039 P698 "31948903" @default.
- Q92710039 P921 Q108853737 @default.
- Q92710039 P921 Q269829 @default.
- Q92710039 P921 Q42824827 @default.